Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies.

Vardon A, Dandapani M, Cheng D, Cheng P, De Santo C, Mussai F.

Oncotarget. 2017 Jun 29;8(38):63506-63517. doi: 10.18632/oncotarget.18843. eCollection 2017 Sep 8.

2.

A standardized and reproducible protocol for serum-free monolayer culturing of primary paediatric brain tumours to be utilized for therapeutic assays.

Sandén E, Eberstål S, Visse E, Siesjö P, Darabi A.

Sci Rep. 2015 Jul 17;5:12218. doi: 10.1038/srep12218.

3.

An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes.

Mohankumar KM, Currle DS, White E, Boulos N, Dapper J, Eden C, Nimmervoll B, Thiruvenkatam R, Connelly M, Kranenburg TA, Neale G, Olsen S, Wang YD, Finkelstein D, Wright K, Gupta K, Ellison DW, Thomas AO, Gilbertson RJ.

Nat Genet. 2015 Aug;47(8):878-87. doi: 10.1038/ng.3323. Epub 2015 Jun 15.

4.

Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma.

Griesinger AM, Josephson RJ, Donson AM, Mulcahy Levy JM, Amani V, Birks DK, Hoffman LM, Furtek SL, Reigan P, Handler MH, Vibhakar R, Foreman NK.

Cancer Immunol Res. 2015 Oct;3(10):1165-74. doi: 10.1158/2326-6066.CIR-15-0061. Epub 2015 May 12.

5.

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.

Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR.

J Immunother Cancer. 2014 Dec 16;2(1):46. doi: 10.1186/s40425-014-0046-9. eCollection 2014.

6.

Dual roles for immune metagenes in breast cancer prognosis and therapy prediction.

Alistar A, Chou JW, Nagalla S, Black MA, D'Agostino R Jr, Miller LD.

Genome Med. 2014 Oct 28;6(10):80. doi: 10.1186/s13073-014-0080-8. eCollection 2014.

7.

Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children.

Shevtsov MA, Kim AV, Samochernych KA, Romanova IV, Margulis BA, Guzhova IV, Yakovenko IV, Ischenko AM, Khachatryan WA.

Onco Targets Ther. 2014 Jun 18;7:1071-81. doi: 10.2147/OTT.S62764. eCollection 2014.

8.

Immunotherapeutic implications of the immunophenotype of pediatric brain tumors.

Griesinger AM, Donson AM, Foreman NK.

Oncoimmunology. 2014 Jan 1;3(1):e27256.

9.

Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma.

Hoffman LM, Donson AM, Nakachi I, Griesinger AM, Birks DK, Amani V, Hemenway MS, Liu AK, Wang M, Hankinson TC, Handler MH, Foreman NK.

Acta Neuropathol. 2014 May;127(5):731-45. doi: 10.1007/s00401-013-1212-8. Epub 2013 Nov 17.

10.

Ependymomas: development of immunotherapeutic strategies.

Pollack IF, Jakacki RI, Butterfield LH, Okada H.

Expert Rev Neurother. 2013 Oct;13(10):1089-98. doi: 10.1586/14737175.2013.840420. Review.

11.

Characterization of distinct immunophenotypes across pediatric brain tumor types.

Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH, Foreman NK.

J Immunol. 2013 Nov 1;191(9):4880-8. doi: 10.4049/jimmunol.1301966. Epub 2013 Sep 27.

12.

Multi-study integration of brain cancer transcriptomes reveals organ-level molecular signatures.

Sung J, Kim PJ, Ma S, Funk CC, Magis AT, Wang Y, Hood L, Geman D, Price ND.

PLoS Comput Biol. 2013;9(7):e1003148. doi: 10.1371/journal.pcbi.1003148. Epub 2013 Jul 25.

13.

Emerging evidence of anti-tumor immune control in the central nervous system.

Donson AM, Foreman NK.

Oncoimmunology. 2012 Dec 1;1(9):1648-1649.

14.

Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy.

Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF.

J Neurooncol. 2013 Jan;111(2):103-11. doi: 10.1007/s11060-012-0998-x. Epub 2012 Nov 21.

15.

Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors.

Donson AM, Birks DK, Schittone SA, Kleinschmidt-DeMasters BK, Sun DY, Hemenway MF, Handler MH, Waziri AE, Wang M, Foreman NK.

J Immunol. 2012 Aug 15;189(4):1920-7. doi: 10.4049/jimmunol.1103373. Epub 2012 Jul 16.

16.

A prognostic gene expression signature in infratentorial ependymoma.

Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffietti R, Ledoux A, Wilson C, Long L, Gilbert MR, Aldape K; Collaborative Ependymoma Research Network.

Acta Neuropathol. 2012 May;123(5):727-38. doi: 10.1007/s00401-012-0941-4. Epub 2012 Feb 10.

17.

Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death.

Rogers HA, Kilday JP, Mayne C, Ward J, Adamowicz-Brice M, Schwalbe EC, Clifford SC, Coyle B, Grundy RG.

Acta Neuropathol. 2012 May;123(5):711-25. doi: 10.1007/s00401-011-0904-1. Epub 2011 Nov 23.

18.

Molecular genetics of ependymoma.

Yao Y, Mack SC, Taylor MD.

Chin J Cancer. 2011 Oct;30(10):669-81. doi: 10.5732/cjc.011.10129. Review.

19.

BTECH: a platform to integrate genomic, transcriptomic and epigenomic alterations in brain tumors.

Wang M, Xie H, Stellpflug W, Rajaram V, Bonaldo Mde F, Goldman S, Tomita T, Soares MB.

Neuroinformatics. 2011 Mar;9(1):59-67. doi: 10.1007/s12021-010-9091-9.

20.

Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis.

Peyre M, Commo F, Dantas-Barbosa C, Andreiuolo F, Puget S, Lacroix L, Drusch F, Scott V, Varlet P, Mauguen A, Dessen P, Lazar V, Vassal G, Grill J.

PLoS One. 2010 Sep 24;5(9):e12932. doi: 10.1371/journal.pone.0012932.

Supplemental Content

Support Center